| Entry |
|
| Name |
AREG-overexpression to PI3K signaling pathway
|
| Definition |
AREG* -> EGFR -> PI3K -> PIP3 -> AKT -> S6K |
| Expanded |
374v1 -> 1956 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> (6198,6199) |
| Class |
|
| Type |
Variant
|
| Pathway |
|
| Disease |
|
| Gene |
| 1956 | EGFR; epidermal growth factor receptor |
| 5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| 5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| 207 | AKT1; AKT serine/threonine kinase 1 |
| 208 | AKT2; AKT serine/threonine kinase 2 |
| 10000 | AKT3; AKT serine/threonine kinase 3 |
| 6198 | RPS6KB1; ribosomal protein S6 kinase B1 |
| 6199 | RPS6KB2; ribosomal protein S6 kinase B2 |
|
| Variant |
374v1 (AREG*) AREG overexpression
|
| Metabolite |
| C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
| Reference |
|
| Authors |
Dasari A, Messersmith WA |
| Title |
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. |
| Journal |
|
| Reference |
|
| Authors |
Hutchinson RA, Adams RA, McArt DG, Salto-Tellez M, Jasani B, Hamilton PW |
| Title |
Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. |
| Journal |
|
| Reference |
|
| Authors |
Yarom N, Jonker DJ |
| Title |
The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. |
| Journal |
Discov Med 11:95-105 (2011) |